- Home
- MRAM vs ZNTL Comparison
MRAM vs ZNTL Comparison
Compare MRAM & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- ZNTL
- Stock Information
- Founded
- MRAM 2008
- ZNTL 2014
- Country
- MRAM United States
- ZNTL United States
- Employees
- MRAM N/A
- ZNTL N/A
- Industry
- MRAM Semiconductors
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- MRAM Technology
- ZNTL Health Care
- Exchange
- MRAM Nasdaq
- ZNTL Nasdaq
- Market Cap
- MRAM 114.4M
- ZNTL 102.2M
- IPO Year
- MRAM 2016
- ZNTL 2020
- Fundamental
- Price
- MRAM $5.94
- ZNTL $1.23
- Analyst Decision
- MRAM Strong Buy
- ZNTL Buy
- Analyst Count
- MRAM 2
- ZNTL 8
- Target Price
- MRAM $9.00
- ZNTL $8.53
- AVG Volume (30 Days)
- MRAM 73.3K
- ZNTL 752.0K
- Earning Date
- MRAM 04-30-2025
- ZNTL 05-20-2025
- Dividend Yield
- MRAM N/A
- ZNTL N/A
- EPS Growth
- MRAM N/A
- ZNTL N/A
- EPS
- MRAM N/A
- ZNTL N/A
- Revenue
- MRAM $49,110,000.00
- ZNTL $67,425,000.00
- Revenue This Year
- MRAM $8.07
- ZNTL N/A
- Revenue Next Year
- MRAM $17.98
- ZNTL N/A
- P/E Ratio
- MRAM N/A
- ZNTL N/A
- Revenue Growth
- MRAM N/A
- ZNTL N/A
- 52 Week Low
- MRAM $4.34
- ZNTL $1.01
- 52 Week High
- MRAM $7.00
- ZNTL $13.24
- Technical
- Relative Strength Index (RSI)
- MRAM 66.98
- ZNTL 38.08
- Support Level
- MRAM $5.57
- ZNTL $1.33
- Resistance Level
- MRAM $6.15
- ZNTL $1.32
- Average True Range (ATR)
- MRAM 0.25
- ZNTL 0.10
- MACD
- MRAM 0.07
- ZNTL -0.00
- Stochastic Oscillator
- MRAM 80.37
- ZNTL 8.22
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.